Compare RNA & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RNA | NERV |
|---|---|---|
| Founded | 2012 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 222.5M | 210.1M |
| IPO Year | 2025 | 2014 |
| Metric | RNA | NERV |
|---|---|---|
| Price | $12.29 | $4.48 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 2 |
| Target Price | ★ $69.26 | $10.50 |
| AVG Volume (30 Days) | 229.2K | ★ 379.3K |
| Earning Date | 01-01-0001 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,175,600.00 |
| Revenue This Year | $88.12 | N/A |
| Revenue Next Year | $18.11 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.40 | $1.76 |
| 52 Week High | $73.06 | $12.46 |
| Indicator | RNA | NERV |
|---|---|---|
| Relative Strength Index (RSI) | 44.86 | 47.36 |
| Support Level | $11.95 | $3.77 |
| Resistance Level | $14.05 | $4.59 |
| Average True Range (ATR) | 0.51 | 0.39 |
| MACD | -0.09 | -0.01 |
| Stochastic Oscillator | 31.74 | 34.16 |
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.
Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.